{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:49:42Z","timestamp":1790880582128,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Discipline Innovation Fund of the First Affiliated Hospital of Chongqing Medical University"},{"name":"the Project of Joint Medical Scientific Research of Chongqing Science and Technology Commission and Chongqing Health Commission","award":["2021MSXM219"],"award-info":[{"award-number":["2021MSXM219"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autologous stem cell transplantation (ASCT) is an important treatment for peripheral T-cell lymphoma (PTCL) patients both during front and salvage therapy. In order to explore the appropriate conditioning regiments and seek ways to improve the efficacy and safety of PTCL, we retrospectively compared the outcomes of 52 PTCL patients treated with CEAC (lomustine, etoposide, cytarabine and cyclophosphamide; n\u2009=\u200928), BEAM (carmustine, etoposide, cytarabine and melphalan; n\u2009=\u200914) and IEAC (idarubicin, etoposide, cytarabine and cyclophosphamide; n\u2009=\u200910) regimens followed by ASCT at our center between 2012 and 2021. Although the time of neutrophil engraftment in CEAC group was earlier than that in IEAC group (<jats:italic>P<\/jats:italic>\u2009=\u20090.042) and platelet infusion in BEAM group was significantly more than CEAC group (<jats:italic>P<\/jats:italic>\u2009=\u20090.042), there were no significant difference in platelet engraftment, hematopoietic engraftment and red blood cells infusion among the 3 groups. The transplantation related mortality rate (TRM) and the early overall response rate (ORR) was 3.8% and 85.7% respectively. The 5-year OS and PFS was 62.8% (95% CI: 54.8\u201370.8%) and 61.0% (95% CI: 53.1\u201368.9%) respectively. There was no significant difference in TRM, ORR and survival among the 3 groups. Univariate and multivariate analysis showed that high PIT score (the T cell lymphoma prognostic index,\u2009&gt;\u20091) and failure to reach complete response (non-CR) at 3\u00a0months after ASCT were common risk factors for OS (<jats:italic>P<\/jats:italic>\u2009=\u20090.036 and 0.007) and PFS (<jats:italic>P<\/jats:italic>\u2009=\u20090.021 and 0.012). In conclusion, CEAC and IEAC regimen can be used as alternative conditioning regiments for ASCT in PTCL patients, and their efficacy and safety are comparable to BEAM regiment. Patients with high PIT score and non-CR early after ASCT had worse outcomes.<\/jats:p>","DOI":"10.1038\/s41598-022-18540-x","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T11:02:59Z","timestamp":1661252579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients"],"prefix":"10.1038","volume":"12","author":[{"given":"Yi-Ying","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"18540_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage, J. O., Gascoyne, R. D., Lunning, M. A. & Cavalli, F. Non-Hodgkin lymphoma. Lancet 390, 298\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(16)32407-2 (2017).","journal-title":"Lancet"},{"key":"18540_CR2","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1182\/blood-2019-129664","volume":"134","author":"H Cho","year":"2019","unstructured":"Cho, H. et al. Current treatment patterns and outcomes in patients with peripheral T-cell lymphoma: Updated results of the nationwide, multi-center prospective registry study (CISL 1404). Blood 134, 2844\u20132844. https:\/\/doi.org\/10.1182\/blood-2019-129664 (2019).","journal-title":"Blood"},{"key":"18540_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.hoc.2019.04.002","volume":"33","author":"SY Ng","year":"2019","unstructured":"Ng, S. Y. & Jacobsen, E. D. Peripheral T-cell lymphoma: moving toward targeted therapies. Hematol. Oncol. Clin. North Am. 33, 657\u2013668. https:\/\/doi.org\/10.1016\/j.hoc.2019.04.002 (2019).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"18540_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3109\/10428194.2013.852666","volume":"55","author":"A Cairoli","year":"2014","unstructured":"Cairoli, A., Ketterer, N., Barelli, S. & Duchosal, M. A. High-dose therapy and autologous hematopoietic stem cell transplant in T-cell lymphoma: A single center experience. Leuk Lymphoma 55, 1827\u20131831. https:\/\/doi.org\/10.3109\/10428194.2013.852666 (2014).","journal-title":"Leuk Lymphoma"},{"key":"18540_CR5","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/blood.2020008825","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz, N. et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood 137, 2646\u20132656. https:\/\/doi.org\/10.1182\/blood.2020008825 (2021).","journal-title":"Blood"},{"key":"18540_CR6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41409-020-01160-2","volume":"56","author":"G-Y Song","year":"2021","unstructured":"Song, G.-Y. et al. Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK\/T-cell lymphoma. Bone Marrow Transpl. 56, 1205\u20131208. https:\/\/doi.org\/10.1038\/s41409-020-01160-2 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"18540_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.16766\/j.cnki.issn.1674-4152.001168","volume":"28","author":"C Dong","year":"2020","unstructured":"Dong, C. et al. Efficacy and prognosis of autologous hematopoietic stem cell transplantation in treating recurrent refractory peripheral T cell lymphoma. Chin. J. Gen. Pract. 28, 59-61,157. https:\/\/doi.org\/10.16766\/j.cnki.issn.1674-4152.001168 (2020).","journal-title":"Chin. J. Gen. Pract."},{"key":"18540_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3760\/cma.j.issn.0253-2727.2021.05.014","volume":"42","author":"J Yang","year":"2021","unstructured":"Yang, J. et al. A comparative analysis of autologous hematopoietic stem cell transplantation and chemotherapy alone in the treatment of nodal peripheral T-cell lymphoma in complete remission. Clin. J. Hematol. 42, 428\u2013431. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2021.05.014 (2021).","journal-title":"Clin. J. Hematol."},{"key":"18540_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park, S. I. et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer 125, 1507\u20131517. https:\/\/doi.org\/10.1002\/cncr.31861 (2019).","journal-title":"Cancer"},{"key":"18540_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jtct.2021.04.002","volume":"27","author":"YL Boo","year":"2021","unstructured":"Boo, Y. L. & Koh, L. P. Hematopoietic stem cell transplantation in T-cell and NK-cell lymphomas\u2013update on recent advances: ScienceDirect. Transpl. Cell. Ther. 27, 571\u2013588. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.002 (2021).","journal-title":"Transpl. Cell. Ther."},{"key":"18540_CR11","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.16016\/j.1000-5404.201905099","volume":"41","author":"Y Yichun","year":"2019","unstructured":"Yichun, Y. et al. Efficacy of CEAC regimen before autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma: Analysis of 102 cases. J. Amry Med. Univ. 41, 2272\u20132279. https:\/\/doi.org\/10.16016\/j.1000-5404.201905099 (2019).","journal-title":"J. Amry Med. Univ."},{"key":"18540_CR12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.12122\/j.issn.1673-4254.2020.12.10","volume":"40","author":"X Yiying","year":"2020","unstructured":"Yiying, X. et al. IEAC versus CEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for lymphoma: analysis of efficacy and safety in 106 cases. J. South Med. Univ. 40, 1760\u20131767. https:\/\/doi.org\/10.12122\/j.issn.1673-4254.2020.12.10 (2020).","journal-title":"J. South Med. Univ."},{"key":"18540_CR13","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569 (2016).","journal-title":"Blood"},{"key":"18540_CR14","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini, A. et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103, 2474\u20132479. https:\/\/doi.org\/10.1182\/blood-2003-09-3080 (2004).","journal-title":"Blood"},{"key":"18540_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbmt.2013.11.002","volume":"20","author":"YY Xiong","year":"2014","unstructured":"Xiong, Y. Y. et al. Mesenchymal stem cells versus mesenchymal stem cells combined with cord blood for engraftment failure after autologous hematopoietic stem cell transplantation: A pilot prospective, open-label Randomized Trial. Biol. Blood Marrow Transpl. 20, 236\u2013242. https:\/\/doi.org\/10.1016\/j.bbmt.2013.11.002 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"18540_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F. & Lister, T. A. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 32, 3059. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800 (2014).","journal-title":"J. Clin. Oncol."},{"key":"18540_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3969\/j.issn.1000-8179.2020.02.021","volume":"48","author":"L Zhao","year":"2021","unstructured":"Zhao, L. & Ping, I. Advances in the treatment of newly diagnosed peripheral T-cell lymphoma. Chin. J .Clin. Oncol. 48, 100\u2013104. https:\/\/doi.org\/10.3969\/j.issn.1000-8179.2020.02.021 (2021).","journal-title":"Chin. J .Clin. Oncol."},{"key":"18540_CR18","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja, M. A. et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: An international collaborative effort on behalf of the guidelines committee of the american society for blood and marrow transplantation. Biol. Blood Marrow Transpl. 23, 1826\u20131838. https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.027 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"18540_CR19","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s00432-019-02999-9","volume":"145","author":"M Roerden","year":"2019","unstructured":"Roerden, M. et al. The role of autologous stem cell transplantation in peripheral T cell lymphoma: A long-term follow-up single-center experience. J. Cancer Res. Clin. Oncol. 145, 2595\u20132604. https:\/\/doi.org\/10.1007\/s00432-019-02999-9 (2019).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"18540_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard, G. et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann. Oncol. 29, 715\u2013723. https:\/\/doi.org\/10.1093\/annonc\/mdx787 (2018).","journal-title":"Ann. Oncol."},{"key":"18540_CR21","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/10428194.2018.1563691","volume":"60","author":"Z Al-Mansour","year":"2019","unstructured":"Al-Mansour, Z. et al. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leuk Lymphoma 60, 1934\u20131941. https:\/\/doi.org\/10.1080\/10428194.2018.1563691 (2019).","journal-title":"Leuk Lymphoma"},{"key":"18540_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12185-020-02879-w","volume":"112","author":"S Yamasaki","year":"2020","unstructured":"Yamasaki, S. et al. Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. Int. J. Hematol. 112, 74\u201383. https:\/\/doi.org\/10.1007\/s12185-020-02879-w (2020).","journal-title":"Int. J. Hematol."},{"key":"18540_CR23","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","volume":"33","author":"PM Barr","year":"2015","unstructured":"Barr, P. M. et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J. Clin. Oncol. 33, 2399\u20132404. https:\/\/doi.org\/10.1200\/JCO.2014.60.6327 (2015).","journal-title":"J. Clin. Oncol."},{"key":"18540_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ajh.25077","volume":"93","author":"SP Chantepie","year":"2018","unstructured":"Chantepie, S. P. et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am. J. Hematol. 93, 729\u2013735. https:\/\/doi.org\/10.1002\/ajh.25077 (2018).","journal-title":"Am. J. Hematol."},{"key":"18540_CR25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/sj.bmt.1705175","volume":"36","author":"M Ala-Kopsala","year":"2005","unstructured":"Ala-Kopsala, M. et al. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin\u2019s lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transpl. 36, 1077\u20131082. https:\/\/doi.org\/10.1038\/sj.bmt.1705175 (2005).","journal-title":"Bone Marrow Transpl."},{"key":"18540_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1600-0609.2006.00687.x","volume":"77","author":"T Kuittinen","year":"2006","unstructured":"Kuittinen, T. et al. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin\u2019s lymphoma patients undergoing autologous stem cell transplantation. Eur. J. Haematol. 77, 120\u2013127. https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00687.x (2006).","journal-title":"Eur. J. Haematol."},{"key":"18540_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","volume":"141","author":"JS Gottdiener","year":"1981","unstructured":"Gottdiener, J. S., Appelbaum, F. R., Ferrans, V. J., Deisseroth, A. & Ziegler, J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch. Intern. Med. 141, 758\u2013763 (1981).","journal-title":"Arch. Intern. Med."},{"key":"18540_CR28","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/1097-0142(19860515)57:10<2061::aid-cncr2820571031>3.0.co;2-h","volume":"57","author":"B Cazin","year":"1986","unstructured":"Cazin, B. et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 57, 2061\u20132069. https:\/\/doi.org\/10.1002\/1097-0142(19860515)57:10%3c2061::aid-cncr2820571031%3e3.0.co;2-h (1986).","journal-title":"Cancer"},{"key":"18540_CR29","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1038\/s41598-021-81944-8","volume":"11","author":"C Tian","year":"2021","unstructured":"Tian, C. et al. Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin\u2019s lymphoma patients. Sci. Rep. 11, 4273. https:\/\/doi.org\/10.1038\/s41598-021-81944-8 (2021).","journal-title":"Sci. Rep."},{"key":"18540_CR30","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0300060516676725","volume":"45","author":"H Xiao","year":"2017","unstructured":"Xiao, H. et al. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience. J Int Med Res 45, 290\u2013302. https:\/\/doi.org\/10.1177\/0300060516676725 (2017).","journal-title":"J Int Med Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18540-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18540-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18540-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T07:45:06Z","timestamp":1669362306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18540-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18540"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18540-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14369"}}